Abstract 178P
Background
Although splenic hilar lymph node (no.10 LN) dissection did not prolong survival in proximal gastric cancer, B4-type gastric cancer remains uninvestigated for the necessity of no.10 LN dissection. This is the first study investigating the treatment effect of no.10 LN dissection in B4-type gastric cancer.
Methods
We retrospectively reviewed patients who underwent total gastrectomy for B4-type gastric cancer between 2006 and 2016 in four major institutions in Korea. Using the inverse probability of treatment weighting (IPTW) using the propensity score, the long-term survival was compared between patients with and without no.10 LN dissection.
Results
There were 540.4 patients in the no.10-dissection group and 532.69 patients in the no-dissection group in the IPTW sample. The IPTW sample showed well-balanced clinicopathological characteristics between the two groups. The no.10-dissection group showed significantly better survival than the no-dissection group (5-ysr 45.7% vs. 38.6%, p=0.036). Multivariate analysis revealed that no.10 LN dissection was an independent prognostic factor (adjusted hazard ratio [HR] = 0.747, 95% CI = 0.593 – 0.940) after adjusting for other prognostic factors.
Conclusions
No.10 LN dissection during total gastrectomy may prolong survival in B4-type gastric cancer. A large randomized controlled trial may be warranted to validate these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract